Literature DB >> 30031652

Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition.

Shen-Zhen Ren1, Zhong-Chang Wang1, Xiao-Hua Zhu1, Dan Zhu1, Zhang Li1, Fa-Qian Shen1, Yong-Tao Duan2, Han Cao1, Jing Zhao3, Hai-Liang Zhu4.   

Abstract

The overexpress of COX-2 was clearly associated with carcinogenesis and COX-2 as a possible target has long been exploited for cancer therapy. In this work, we described the design and synthesis of a series of diarylpyrazole derivatives integrating with chrysin. Among them, compound e9 exhibited the most potent inhibitory activity against COX-2 and antiproliferative activity against Hela cells with IC50 value of 1.12 μM. Further investigation revealed that e9 could induce apoptosis of Hela cells by mitochondrial depolarization and block the G1 phase of cell cycle in a dose-dependent manner. Besides, molecular docking simulation results was further confirmed that e9 could bind well with COX-2. In summary, compound e9 may be promising candidates for cancer therapy.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiproliferative; COX-2 inhibitor; Chysin; Docking; Pyrazole

Mesh:

Substances:

Year:  2018        PMID: 30031652     DOI: 10.1016/j.bmc.2018.07.022

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Discovery of 3-alkyl-5-aryl-1-pyrimidyl-1H-pyrazole derivatives as a novel selective inhibitor scaffold of JNK3.

Authors:  Youri Oh; Miyoung Jang; Hyunwook Cho; Songyi Yang; Daseul Im; Hyungwoo Moon; Jung-Mi Hah
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 2.  Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives.

Authors:  Ebrahim Rahmani Moghadam; Hui Li Ang; Sholeh Etehad Asnaf; Amirhossein Zabolian; Hossein Saleki; Mohammad Yavari; Hossein Esmaeili; Ali Zarrabi; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  Biomolecules       Date:  2020-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.